52 Chapter 2 2 Data sharing statement Individual de-identified participant data supporting the findings are available from the corresponding author on reasonable request. Acknowledgments The authors thank all participating patients, healthcare professionals, policymakers and developers for their participation in this study. We thank Sander Hermsen for his valuable input on behaviour change strategies and the members of our patient advisory panel (J Donkers, B Frankemölle, J Groenendijk and S Sturkenboom) for their valuable input in the setup and execution of the study. AstraZeneca was provided the opportunity to review the manuscript; full editorial control remained with the authors. Author contributions JdB and CCP conceptualized and designed the study. JdB was responsible for data collection, data analysis and interpretation. CCP, LG, VTV and EM made substantial contributions to the design and collection of data. CCP, EM, SJvH and NHC made substantial contributions to interpretation of data. CCP wrote the manuscript and EM provided feedback at each version of the manuscript. All authors reviewed and agreed on all versions of the article before submission, during revision, the final version accepted for publication, and any significant changes introduced at the proofing stage. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Funding The study is funded by AstraZeneca following a research collaboration agreement. The funding body was not involved in designing the study, data collection, study management nor the analysis and interpretation of data and writing the manuscript. AstraZeneca was provided the opportunity to review the manuscript and full editorial control remained with the authors. Disclosure All authors declare no competing interests in this work.
RkJQdWJsaXNoZXIy MTk4NDMw